Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Abatacept Placebo Clear all
Completed Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Ulcerative Colitis

NCT00410410
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
abatacept (ABA), placebo, abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 2 Interventional Results available

Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

NCT00556439
View directory record Official record
Conditions
Takayasu's Arteritis, Giant Cell Arteritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
15 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
8
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

NCT02915159
View directory record Official record
Conditions
Sjogrens Disease
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Fullerton, California • Riverside, California • Lakewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

NCT01142726
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 2, 2026, 7:24 AM EDT
Recruiting Phase 3 Interventional

Abatacept for the Treatment of Giant Cell Arteritis

NCT04474847
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Rochester, Minnesota • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

NCT00095147
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB, ABA, open-label (OL)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Denver, Colorado • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

NCT00048581
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2011 · Synced Sep 2, 2026, 7:24 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

NCT03733067
View directory record Official record
Conditions
CTLA4 Haploinsufficency, Chronic Cytopenia
Interventions
abatacept, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

NCT02504268
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
42
States / cities
Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 2, 2026, 7:24 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

NCT02232880
View directory record Official record
Conditions
Hypertension
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

NCT01350804
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AIN457, Placebo, Abatacept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
44
States / cities
Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 2, 2026, 7:24 AM EDT
Recruiting Phase 2 Interventional

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

NCT04380740
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Placebo, Abatacept
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

NCT01860976
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Colorado Springs, Colorado • Bridgeport, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 2, 2026, 7:24 AM EDT
Withdrawn Not applicable Interventional

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

NCT02053727
View directory record Official record
Conditions
Rheumatoid Arthritis, Chronic Hepatitis B
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2020 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 2 Interventional Results available

Abatacept With Methotrexate- Phase IIB

NCT00162266
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (BMS-188667), Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 2 Interventional Results available

Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

NCT02270957
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Methotrexate-Inadequate Response Study

NCT00559585
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Subcutaneous (SC) Abatacept, Intravenous (IV) Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
2,492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
70
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2015 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Immune Modulators for Treating COVID-19

NCT04593940
View directory record Official record
Conditions
Covid19
Interventions
Infliximab, Abatacept, Remdesivir, cenicriviroc (closed to enrollment as of 3-Sep-2021)
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
18 Years and older
Enrollment
1,971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
67
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 4 Interventional Results available

Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

NCT05822583
View directory record Official record
Conditions
COVID-19
Interventions
abatacept infusion, Placebo group
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
82
States / cities
Birmingham, Alabama • Tucson, Arizona • Davis, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 2 Interventional Results available

Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients

NCT00124449
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Abatacept, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
20
States / cities
Huntsville, Alabama • Mobile, Alabama • Huntington Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

NCT00048568
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2011 · Synced Sep 2, 2026, 7:24 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of COYA 302 for the Treatment of ALS

NCT07161999
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
COYA 302, Placebo
Drug
Lead sponsor
Coya Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 2 Interventional Results available

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

NCT00774852
View directory record Official record
Conditions
Lupus Nephritis, Lupus Erythematosus, Systemic
Interventions
abatacept, cyclophosphamide, azathioprine, prednisone, abatacept placebo, azathioprine placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 2, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

NCT02971683
View directory record Official record
Conditions
Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy, Overlap Myositis, Juvenile Myositis Above the Age of 18
Interventions
Abatacept subcutaneous, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • Beverly Hills, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 2, 2026, 7:24 AM EDT